Business Context and Reporting Period
Company: Daré Bioscience, Inc. (Nasdaq: DARE)
Filing Type: Form 8-K (Current Report)
Date of Report: December 16, 2024
Primary Business: Clinical-stage biopharmaceutical company focused on developing treatments for female sexual arousal disorder (FSAD). The filing details Phase 3 clinical development plans for its investigational topical cream, Sildenafil Cream, 3.6%.
Key Financial Metrics
This Form 8-K is a current report regarding regulatory and clinical developments. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. Investors should refer to the company's most recent Form 10-Q (filed November 14, 2024) or Form 10-K for financial metrics.
Material Changes and Clinical Updates
- FDA Engagement: The Company announced Phase 3 clinical development plans for Sildenafil Cream following discussions with the U.S. Food and Drug Administration (FDA).
- Submission Timeline: Daré plans to submit the protocol and statistical analysis plan for an adequate and well-controlled Phase 3 clinical study to the FDA in the first quarter of 2025.
- Study Commencement: The Company targets mid-2025 for the commencement of the Phase 3 study.
- Study Design:
- Population: Premenopausal women with FSAD.
- Duration: 12-week double-blind treatment period comparing Sildenafil Cream to placebo.
- Endpoints: Co-primary endpoints assessing arousal sensations and associated distress (consistent with the Phase 2b RESPOND study). Secondary endpoints include improvement in orgasm, desire, distress, and interpersonal difficulties.
- Regulatory Pathway: A second confirmatory Phase 3 study will be required to support a New Drug Application (NDA) submission.
Guidance, Outlook, and Risks
Outlook: Management expects the Phase 3 trial design to reflect FDA recommendations and aims to advance the product toward potential FDA approval for the treatment of FSAD in premenopausal women.
Key Risks and Uncertainties:
- Clinical Trial Failure: Risk that the Phase 3 study may fail to demonstrate statistically significant differences between Sildenafil Cream and placebo, similar to risks noted in the Phase 2b study.
- Capital Resources: Potential insufficiency of capital to advance development on communicated timelines or to continue as a going concern.
- Regulatory Approval: Uncertainty regarding FDA acceptance of data interpretation and the requirement for additional studies.
- Operational Risks: Dependence on third parties for manufacturing and clinical trial conduct; potential delays in patient enrollment.
Investor Verification Checklist
- Verify the specific date of the Phase 3 protocol submission to the FDA in Q1 2025.
- Confirm the Company's current cash runway and capital raise plans to fund the Phase 3 studies, as this filing does not provide liquidity data.
- Review the detailed risk factors in the most recent Form 10-K and 10-Q regarding the complexity of FSAD clinical trials.
- Monitor the timeline for the second confirmatory Phase 3 study required for NDA submission.
- Assess the Company's ability to secure necessary intellectual property rights and satisfy monetary obligations under in-license agreements.